Investigation of a novel radionuclide carrier for targeted radionuclide therapy

Background: In internal radiation therapy of cancer, optimal targeting ligand and type therapeutic radionuclide must be considered carefully for effective treatment. addition, nuclide may vary depending on diverse parameters characterizing the tumor. Thus, use in various cancers, there is a need development carrier that can firmly bind to variety nuclides. Here we introduce biocompatible iron oxide nano carrier. By reacting nanoparticles nuclides using our conjugate synthesizer, it possible near-permanently nanocarriers. Material methods: To test carrier’s biocompatibility, particles were labeled with fluorescence dye injected intravenously into female CD-1 mice. Mice anesthetized biodistribution was recorded. binding capabilities, carriers radiolabeled radioactive iodine mice scanned single-photon emission computed tomography (SPECT). Ligand-mediated cellular uptake demonstrated per content human origin cancer cells qualitatively through Prussian blue staining quantitatively by ICP-MS. Results: As result studies, circulated body during initial time points rapidly excreted kidney could detected bladder at 3 hours post-injection. Rapid excretion allows lowered whole-body toxicity. SPECT data showed stable distribution throughout whole body. Given normal free radioiodine accumulate thyroid, such evidence firm Ligand-receptor-mediated nanocarriers increased dose-dependently up 24 post-treatment. Conclusions: have introduced Its near-permanent properties make an admirable platform targeted therapy. Further vivo studies been carried out application treating triple-negative breast cancers (TNBC) platinum-resistant ovarian using131I folic acid ligands. No conflict interest.